Molecular Imaging and Biology

, Volume 11, Issue 5, pp 303–307 | Cite as

Replacing 99mTc with 111In Improves MORF/cMORF Pretargeting by Reducing Intestinal Accumulation

  • Guozheng Liu
  • Dengfeng Cheng
  • Shuping Dou
  • Xiangji Chen
  • Minmin Liang
  • P. Hendrik Pretorius
  • Mary Rusckowski
  • Donald J. Hnatowich
Brief Article

Abstract

Purpose

To reduce accumulation in the abdomen by MORF/cMORF pretargeting, 111In was compared to 99mTc as the radiolabel.

Procedures

After receiving either 99mTc (MAG3)-cMORF or 111In (DTPA)-cMORF, normal mice were imaged and killed for pharmacokinetics. Thereafter, tumored mice were pretargeted with MORF-antibody, 48 h later were given an injection of 99mTc- or 111In-cMORF, and finally were imaged repeatedly.

Results

The cMORF biodistribution in both normal and pretargeted tumored mice was influenced by its radiolabel. While excretion of both 99mTc-cMORF and 111In-cMORF was rapid and mainly through the kidneys, about 2% of 99mTc accumulated in the intestines compared to essentially no intestinal accumulation for 111In at any time. Tumor accumulation was unchanged.

Conclusion

In applications of MORF/cMORF pretargeting intended to image organs deep within the abdomen such as the pancreas, radiolabeling with 111In may be superior to 99mTc.

Key words

Pretargeting Anticancer Antibodies Tumor Radioimmunotargeting 

Notes

Acknowledgment

The authors are grateful to Dr Jeffery Schlom (Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, NIH, Bethesda, MD) for providing the CC49 hybridoma. Financial support was from the National Institute of Health and Juvenile Diabetes Research Foundation International (CA94994, CA107360, and JDRF 37-2009-7).

References

  1. 1.
    Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM (2005) Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 11:7879–7885PubMedCrossRefGoogle Scholar
  2. 2.
    Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11:1250–1255PubMedCrossRefGoogle Scholar
  3. 3.
    Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW (2003) Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101:2340–2348PubMedCrossRefGoogle Scholar
  4. 4.
    Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallett R, Theodore LJ, Stayton PS, Press OW (2003) Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 44:437–445PubMedGoogle Scholar
  5. 5.
    Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, Koch P, Maecke HR, Brancato R, Siccardi AG, Fazio F (1996) Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 37:967–971PubMedGoogle Scholar
  6. 6.
    Robert AS, Cokkinides V, Harmon JE (2006) American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 56:11–25CrossRefGoogle Scholar
  7. 7.
    Buchsbaum DJ (1995) Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 55:5729s–5732sPubMedGoogle Scholar
  8. 8.
    Hiltunen JV (1993) Search for new and improved radiolabeling methods for monoclonal antibodies. A review of different methods. Acta Oncol 32:831–839PubMedCrossRefGoogle Scholar
  9. 9.
    Quadri SM, Vriesendorp HM (1998) Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. Q J Nucl Med 42:250–261PubMedGoogle Scholar
  10. 10.
    Quadri SM, Vriesendorp HM, Leichner PK, Williams JR (1993) Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med 34:938–945PubMedGoogle Scholar
  11. 11.
    Liu G, Dou S, Pretorius PH, Liu X, Rusckowski M, Hnatowich DJ (2008) Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur J Nucl Med Mol Imaging 35:272–280PubMedCrossRefGoogle Scholar
  12. 12.
    Liu G, Dou S, Mardirossian G, He J, Zhang S, Liu X, Rusckowski M, Hnatowich DJ (2006) Successful radiotherapy of tumor in pretargeted mice by 188Re radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analog. Clin Can Res 12:4958–1964CrossRefGoogle Scholar
  13. 13.
    Liu G, Dou S, He J, Yin D, Gupta S, Zhang S, Wang Y, Rusckowski M, Hnatowich DJ (2006) Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot 64:971–978PubMedCrossRefGoogle Scholar
  14. 14.
    Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ (2007) Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging 34:237–246PubMedCrossRefGoogle Scholar
  15. 15.
    Duncan JR, Behr TM, DeNardo SJ (1997) Intracellular fate of radiometals. J Nucl Med 38:829PubMedGoogle Scholar
  16. 16.
    Duncan JR, Stephenson MT, Wu HP, Anderson CJ (1997) Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, hepatocyte lysosomes. Cancer Res 57:659–671PubMedGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2009

Authors and Affiliations

  • Guozheng Liu
    • 1
  • Dengfeng Cheng
    • 1
  • Shuping Dou
    • 1
  • Xiangji Chen
    • 1
  • Minmin Liang
    • 1
  • P. Hendrik Pretorius
    • 1
  • Mary Rusckowski
    • 1
  • Donald J. Hnatowich
    • 1
  1. 1.Division of Nuclear Medicine, Department of RadiologyUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations